Skip to content
i2E
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
  • Programs
    • E3
    • ACT Tulsa
    • Love’s Entrepreneur’s Cup
    • OKBio
  • Client Portfolio
  • Services
    • Access to Funding
    • Venture Advisory Services
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Contact
  • Media
Search

Anti-brain tumor drug gives hope

Get in Touch

By Greg Elwell

Copyright © 2013, The Oklahoma Publishing Company

An anti-brain tumor drug developed at the Oklahoma Medical Research Foundation could prove more effective than current therapies because it attacks cancer cells at multiple key points.

A compound developed by OMRF scientist Dr. Rheal Towner has shown success in fighting extremely aggressive brain tumors in rats and in human cells. PHOTO PROVIDED.

A paper by OMRF scientists Rheal Towner, Ph.D., and Robert Floyd, Ph.D., published in the journal “Neuro-Oncology” showed OKN007 was successful when pitted against extremely aggressive glioma tumors in rats and in human cells.

“One of the main dangers of gliomas is their ability to keep growing. Not only are they getting bigger, but they’re marshaling resources by growing blood vessels, invading cells and turning off the process that tells cells when to die,” Towner said. “We’ve found that OKN007 targets all of these factors.”

Most anti-cancer drugs are aimed at one specific gene, he said. But cancers are resourceful and can devise multiple ways to survive, which is why a multi-target drug might be more successful.

In the parlance of old Westerns, it cuts tumors off at the pass by stunting several growth mechanisms, Towner said.

Their tests showed the compound was able to:

Trigger apoptosis, also known as programmed cell death, which is often turned off in cancer cells.

• Stop angiogenesis, which is the growth of new blood vessels that would feed the cancer.

• Block cell invasion, keeping other cells safe from being taken over by the disease.

Each avenue to growth that is shut down makes it harder for cancer cells to compensate, lowering the risk that the cancer will survive the treatment.

“We think OKN007 could be used on its own or in conjunction with single-target drugs,” he said.

Randy L. Jensen, M.D., Ph.D., of the Huntsman Cancer Institute at the University of Utah contributed to the research.

The research was supported by grant No. AR092-049 from the Oklahoma Center for the Advancement of Science and Technology and Huntsman Cancer Center support grant P30CA042014 from the National Cancer Institute, part of the National Institutes of Health.

Greg Elwell is a public affairs specialist at Oklahoma Medical Research Foundation.

Click here to read the story at newsok.com

  • admin
    admin

More News

Loading...
Black doctor smiling with stethoscope
Blog, i2E
02.09.23

Titan Intake Automates Patient Referrals to Accelerate Care

Read more
man and woman reviewing paperwork at a table
Blog, i2E, News
01.10.23

Stories of Oklahoma Innovation: Building a Startup

Read more
woman in lab conducting a study
Blog, i2E
12.13.22

Bayesic Technologies Improves Effectiveness and Efficiency of Data Analysis in Healthcare

Read more
Bison grazing fields
Blog
11.30.22

Bison Underground Merges Nature, Science, and Technology to Tackle Climate Change

Read more
African American family sitting on couch reading and chatting
Blog, E3, i2E
11.22.22

Fokes Connects Families, Caregivers and Care Agencies for Smoother Communications and Care 

Read more
i2e blog post graphic
Blog, News
11.03.22

Introducing: Stories of Oklahoma Innovation

Read more
Default Featured Image
OKBio
06.28.22

Oklahoma Grown! i2E Invests in BIO startups

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma Medical Research Foundation BIO

Read more
Default Featured Image
OKBio
06.13.22

Moleculera Labs BIO

Read more
Default Featured Image
OKBio
06.13.22

University of Oklahoma Health Sciences Center BIO

Read more
Default Featured Image
OKBio
06.13.22

Oklahoma State University BIO

Read more
Default Featured Image
OKBio
06.13.22

ECHO Investment Capital BIO

Read more
i2E

Oklahoma City Office

840 Research Parkway, Suite 250
OKC, OK 73104
+1 (405) 235.2305

Tulsa Office

100 S. Cincinnati Ave – Suite 514
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources

© 2022 i2E Privacy Policy

Follow us:

Facebook Twitter Linkedin

Programs

  • E3
  • ACT Tulsa
  • Love's Entrepreneur's Cup
  • OKBio
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E